Details of the Drug Combinations

General Information of This Drug (ID: DMCS6M5)

Drug Name

Voxelotor DMCS6M5

Synonyms

Hemoglobin Modulators-1; 1446321-46-5; UNII-3ZO554A4Q8; GBT 440; 3ZO554A4Q8; 2-hydroxy-6-([2-[1-(propan-2-yl)-1H-pyrazol-5-yl]pyridin-3-yl]methoxy)benzaldehyde; 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde; 2-hydroxy-6-((2-(1-(propan-2-yl)-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde; Voxelotor [USAN]; SCHEMBL15065529; Voxelotor(GBT440, GTx011); GTX-011; GBT-440; MolPort-044-830-677; FWCVZAQENIZVMY-UHFFFAOYSA-N; AKOS030526545; ZINC145969085; CS-5317; HY-18681; DA-44587; S

Indication

Disease Entry	ICD 11	Status	REF
Sickle-cell disorder	3A51	Approved	[1]
------------------------------------------------------------------------------------

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Voxelotor + Metformin	DC3L5GX	Metformin	Sickle Cell Disease	[2]
------------------------------------------------------------------------------------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
2	ClinicalTrials.gov (NCT05981365) Voxelotor CYP and Transporter Cocktail Interaction Study